Loading stock data…
$6.34+0.24 (+4.02%)
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs.
YD Bio Ltd in the Healthcare sector is trading at $6.25 with a market capitalization of $301M. The stock is currently 72% below its 52-week high of $22.00, remaining 5.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q4 2025 | Q2 2025 |
|---|---|---|---|
| Total Revenue | — | — | — |
| Gross Profit | — | — | — |
| Operating Income | — | — | — |
| Net Income | — | — | — |
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Tai...